{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"147.0","upperLimit":"2000.0","value":"2000.0"},{"groupId":"OG001","lowerLimit":"628.1","upperLimit":"2000.0","value":"2000.0"},{"groupId":"OG002","lowerLimit":"434.2","upperLimit":"2000.0","value":"2000.0"},{"groupId":"OG003","lowerLimit":"541.0","upperLimit":"2000.0","value":"2000.0"}]}],"title":"IP-10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"463.8","value":"33.1"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"3306.0","value":"31.1"},{"groupId":"OG002","lowerLimit":"1.0","upperLimit":"406.8","value":"17.3"},{"groupId":"OG003","lowerLimit":"1.0","upperLimit":"534.6","value":"44.1"}]}],"title":"Granzyme B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"537796.8","upperLimit":"2424877.7","value":"792754.3"},{"groupId":"OG001","lowerLimit":"557025.0","upperLimit":"7495123.2","value":"1322829.3"},{"groupId":"OG002","lowerLimit":"544589.3","upperLimit":"4588974.8","value":"989188.4"},{"groupId":"OG003","lowerLimit":"256768.6","upperLimit":"4879749.7","value":"1009966.4"}]}],"title":"ICAM-1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"81.1","upperLimit":"1876.0","value":"792.0"},{"groupId":"OG001","lowerLimit":"32.4","upperLimit":"1876.0","value":"493.8"},{"groupId":"OG002","lowerLimit":"7.5","upperLimit":"1876.0","value":"364.9"},{"groupId":"OG003","lowerLimit":"65.0","upperLimit":"1876.0","value":"1857.2"}]}],"title":"IFN-gamma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"544.3","upperLimit":"4000.0","value":"2173.3"},{"groupId":"OG001","lowerLimit":"510.8","upperLimit":"4000.0","value":"2371.2"},{"groupId":"OG002","lowerLimit":"649.9","upperLimit":"4000.0","value":"1999.9"},{"groupId":"OG003","lowerLimit":"653.7","upperLimit":"4000.0","value":"2160.5"}]}],"title":"IL-1 RA"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"91.0","value":"18.4"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"123.1","value":"25.0"},{"groupId":"OG002","lowerLimit":"0.9","upperLimit":"63.7","value":"13.4"},{"groupId":"OG003","lowerLimit":"0.9","upperLimit":"189.4","value":"20.0"}]}],"title":"IL-2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2189.0","upperLimit":"34044.5","value":"16872.7"},{"groupId":"OG001","lowerLimit":"78.0","upperLimit":"100000.0","value":"14383.7"},{"groupId":"OG002","lowerLimit":"78.0","upperLimit":"66024.6","value":"7817.3"},{"groupId":"OG003","lowerLimit":"3002.6","upperLimit":"100000.0","value":"12386.4"}]}],"title":"IL-2 R alpha"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"976.0","value":"305.3"},{"groupId":"OG001","lowerLimit":"3.5","upperLimit":"976.0","value":"89.4"},{"groupId":"OG002","lowerLimit":"3.6","upperLimit":"976.0","value":"44.6"},{"groupId":"OG003","lowerLimit":"13.3","upperLimit":"976.0","value":"921.8"}]}],"title":"IL-6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.2","upperLimit":"71.5","value":"51.5"},{"groupId":"OG001","lowerLimit":"13.8","upperLimit":"153.5","value":"38.9"},{"groupId":"OG002","lowerLimit":"27.9","upperLimit":"98.8","value":"44.1"},{"groupId":"OG003","lowerLimit":"19.1","upperLimit":"83.8","value":"38.8"}]}],"title":"IL-7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.1","upperLimit":"750.0","value":"86.4"},{"groupId":"OG001","lowerLimit":"14.2","upperLimit":"750.0","value":"118.4"},{"groupId":"OG002","lowerLimit":"9.8","upperLimit":"750.0","value":"77.2"},{"groupId":"OG003","lowerLimit":"10.3","upperLimit":"750.0","value":"120.9"}]}],"title":"IL-8"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"614.0","value":"52.5"},{"groupId":"OG001","lowerLimit":"0.7","upperLimit":"466.0","value":"43.9"},{"groupId":"OG002","lowerLimit":"0.7","upperLimit":"263.6","value":"18.8"},{"groupId":"OG003","lowerLimit":"1.8","upperLimit":"466.0","value":"48.2"}]}],"title":"IL-10"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"271.3","value":"57.1"},{"groupId":"OG001","lowerLimit":"13.1","upperLimit":"226.6","value":"56.5"},{"groupId":"OG002","lowerLimit":"11.3","upperLimit":"195.2","value":"47.6"},{"groupId":"OG003","lowerLimit":"21.9","upperLimit":"537.3","value":"50.3"}]}],"title":"IL-15"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2582.7","upperLimit":"20724.3","value":"5389.0"},{"groupId":"OG001","lowerLimit":"2282.3","upperLimit":"39818.9","value":"11309.5"},{"groupId":"OG002","lowerLimit":"2332.6","upperLimit":"31857.7","value":"8278.7"},{"groupId":"OG003","lowerLimit":"4327.4","upperLimit":"30575.9","value":"15411.9"}]}],"title":"Perforin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"443.1","value":"10.5"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"166.9","value":"8.6"},{"groupId":"OG002","lowerLimit":"2.2","upperLimit":"44.9","value":"6.8"},{"groupId":"OG003","lowerLimit":"3.3","upperLimit":"52.1","value":"10.9"}]}],"title":"TNF alpha"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"609223.2","upperLimit":"8424222.9","value":"1387033.6"},{"groupId":"OG001","lowerLimit":"642372.6","upperLimit":"3859375.8","value":"1478356.8"},{"groupId":"OG002","lowerLimit":"634769.7","upperLimit":"2864040.2","value":"1058453.9"},{"groupId":"OG003","lowerLimit":"721050.0","upperLimit":"5184238.4","value":"1367940.7"}]}],"title":"VCAM-1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"38"}],"units":"Participants"}],"description":"Peak was defined as the maximum post-baseline level of the cytokine. Following key cytokines were measured: interferon-gamma induced protein 10 (IP-10), ferritin, granzyme B, intercellular adhesion molecule (ICAM-1), interferon-gamma (IFN-gamma), interleukin-1 receptor antagonist (IL-1RA), IL-2, interleukin-2 receptor alpha (IL-2 R alpha), IL-6, IL-7, IL-8, IL-10, IL-15, perforin, tumor necrosis factor alpha (TNF alpha), and vascular cell adhesion molecule- 1 (VCAM-1).","dispersionType":"Full Range","groups":[{"description":"Participants with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL) received conditioning chemotherapy (fludarabine 30 mg/m\\^2 intravenously \\[IV\\] over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel chimeric antigen receptor (CAR) transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of body weight (BW) on Day 0.","id":"OG000","title":"Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy"},{"description":"Participants with refractory DLBCL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0.","id":"OG001","title":"Phase 2 (Pivotal Study): Cohort 1"},{"description":"Participants with refractory PMBCL or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0..","id":"OG002","title":"Phase 2 (Pivotal Study): Cohort 2"},{"description":"Participants with relapsed or refractory transplant ineligible DLBCL, PMBCL, or TFL received conditioning chemotherapy (fludarabine 30 mg/m\\^2 IV over 30 minutes and cyclophosphamide 500 mg/m\\^2 IV over 60 minutes) on Days -5, -4, and -3; followed by a single infusion of axicabtagene ciloleucel CAR transduced autologous T cells administered IV at a target dose of 2 x 10\\^6 anti-CD19 CAR T cells/kg of BW on Day 0. Participants also received a prophylactic regimen of levetiracetam (750 mg orally or IV twice daily (BID) starting on Day 0) and tocilizumab (8 mg/kg IV over 1 hour (not to exceed 800 mg)) on Day 2).","id":"OG003","title":"Phase 2 (Safety Management Study): Cohort 3"}],"paramType":"MEDIAN","populationDescription":"Participants in the Safety Analysis Set were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 3","title":"Pharmacodynamics: Peak Level of Cytokines in Serum (Phase 1 and Phase 2 Cohorts 1, 2, and 3)","type":"SECONDARY","unitOfMeasure":"pg/mL"}